美鼎生物 VIVO 深 沪
等待开盘 01-30 09:30:00 美东时间
33.97
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 33.97
- 总市值 14.95亿
- 52周最高 34.375
- 市盈率 静 35.50
- 换手率 0.00%
- 52周最低 23.444
- 委 比 0.00%
- 总股本 4400.82万
- 历史最高 34.375
- 量 比 0
- 振 幅 0.00%
- 历史最低 5.51
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Vivos Therapeutics发布新数据显示，其FDA认证的DNA设备能有效缓解儿童ADHD和阻塞性睡眠呼吸暂停（OSA）症状。该设备是非手术、非药物治疗中重度OSA的创新方案，临床试验显示患儿症状改善显著。
2025-09-30 12:30
突然，暴涨！又一巨头，重磅宣布！
下一个超级赛道，或许就是固态电池。 9月18日，松下控股旗下的松下能源公司宣布，将致力于生产被视为新一代电池热门候选的“全固态电池”。此外，据测算这一技术能够使...
2025-09-19 09:29
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics' Vivos DNA appliance, part of the C.A.R.E. line, has been proven safe and effective in treating children with obstructive sleep apnea (OSA) in a multicenter clinical trial published in *The European Journal of Pediatrics*. The study showed that 77% of participants experienced at least a 50% reduction in OSA severity, and 93% of severe cases achieved this reduction. The appliance increases airway volume by 67.8% and reduces slee...
2025-09-17 12:30
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. will release its Q2 2025 financial results after market close on August 19, 2025, followed by a conference call at 5:00 pm ET to discuss results and recent developments. The call can be accessed by dialing (800) 717-1738 (US) or (646) 307-1865 (int'l), with a replay available until September 2, 2025. A live webcast and archive will be available on Vivos' website. The company focuses on treating sleep-related breathing dis...
2025-08-19 12:30
Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction
Catheter Precision stock rocketed higher on Wednesday as investors reacted to i...
2025-06-12 07:44
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), the largest medical sleep center in Nevada, to expand its business model and capture higher-margin revenue. The transaction adds diagnostic and consulting revenues, as well as appliance treatment sales from SCN's patient base, marking Vivos’ first major acquisition of a sleep testing center. Vivos secured over $11 million in financing, inclu...
2025-06-11 12:30
